Shanghai Shengdi Pharmaceutical Co., Ltd

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with locally advanced cervical cancer live longer without the disease getting worse. About 720 participants will receive either adebrelimab or a placebo alongside their standard treatm…

This study tests a new drug called SHR-4610 in about 258 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. Participants will receive the drug and be closely…

This study tests a new contrast agent called HRS-9231 for MRI scans of the brain and spine. About 250 adults with known or suspected brain or spine lesions will receive both HRS-9231 and a standard contrast agent (gadobutrol) in random order. The goal is to see if HRS-9231 is as …